Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Docket		Date Filed	2014-06-02
Court	District Court, D. Delaware	Date Terminated	2017-02-02
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	6,395,767; 7,951,400; 8,628,799; RE44,186
Link to Docket	External link to docket

Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-02				External link to document

AstraZeneca AB v. Mylan Pharmaceuticals Inc. Litigation Summary, 1:14-cv-00696

Last updated: August 14, 2026

AstraZeneca AB v. Mylan Pharmaceuticals Inc., No. 1:14-cv-00696, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Mylan’s abbreviated new drug application for a generic version of FARXIGA, the dapagliflozin product marketed by AstraZeneca. The dispute centered on AstraZeneca’s patents covering dapagliflozin and its use in treating type 2 diabetes.

The litigation reached the U.S. Court of Appeals for the Federal Circuit. The appellate decision, AstraZeneca AB v. Mylan Pharmaceuticals Inc., 809 F.3d 1334 (Fed. Cir. 2016), addressed claim construction and infringement issues involving AstraZeneca’s dapagliflozin patent estate. The case is a significant precedent for interpreting chemical genus claims and assessing whether an ANDA product falls within claims covering a specific pharmaceutical compound.

What drug was at issue in AstraZeneca v. Mylan, 1:14-cv-00696?

The case involved dapagliflozin, an oral sodium-glucose cotransporter-2, or SGLT2, inhibitor.

Item	Data
Brand	FARXIGA
Active ingredient	Dapagliflozin
Sponsor	AstraZeneca
Therapeutic category	Type 2 diabetes; later heart failure and chronic kidney disease indications
FDA approval	Jan. 8, 2014
Regulatory pathway	ANDA patent litigation under the Hatch-Waxman Act
Defendant’s product	Mylan’s proposed generic dapagliflozin product
Court	U.S. District Court for the District of Delaware
Civil action	1:14-cv-00696
Federal Circuit citation	809 F.3d 1334

FARXIGA was initially approved for glycemic control in adults with type 2 diabetes. AstraZeneca later obtained approvals for additional cardiovascular and renal indications, materially expanding the commercial value of the product and its method-of-use patent exposure. [1]

What patents protected FARXIGA in the Mylan litigation?

The principal patent at issue was U.S. Patent No. 6,515,117, which covered C-aryl glucoside compounds, including dapagliflozin.

U.S. Patent No. 6,515,117

The '117 patent was directed to a class of compounds with SGLT2-inhibitory activity. Dapagliflozin was within the claimed chemical genus and was specifically identified in the patent disclosure.

The patent had an expiration date in 2020 before any applicable pediatric exclusivity. The Federal Circuit litigation focused on whether Mylan’s proposed dapagliflozin product infringed the asserted claims and whether the claims were properly construed.

Patent	Subject matter	Approximate ordinary expiration	Litigation relevance
US 6,515,117	C-aryl glucoside compounds, including dapagliflozin	Oct. 2020	Core compound patent asserted against Mylan
US 8,221,786	Dapagliflozin-related treatment methods	2029, subject to patent-term calculation	Later FARXIGA lifecycle protection
Other listed patents	Formulation, combinations and methods of treatment	Various dates	Broader Orange Book estate outside the core 2014 case

The later FARXIGA estate included patents directed to dosing, combination therapy and additional clinical uses. Those patents were not equivalent to the core compound patent. Their value depended on the scope of the ANDA label and the ability to prove infringement based on the proposed product’s indications.

What did the Federal Circuit decide?

The Federal Circuit’s 2016 decision affirmed AstraZeneca’s position on the central infringement dispute. The court held that the asserted patent claims covered dapagliflozin and rejected Mylan’s narrower claim-construction position.

The decision had three commercial consequences:

1. Mylan could not obtain immediate approval based on a claim that its ANDA product fell outside the asserted patent claims.
2. The ruling strengthened AstraZeneca’s ability to enforce the '117 patent against other ANDA applicants using materially similar dapagliflozin products.
3. The decision reduced the value of a non-infringement Paragraph IV strategy directed solely at the chemical scope of the patent.

The case illustrates a recurring ANDA litigation issue: a patent may claim a broad chemical genus, while the generic applicant seeks to market one specific compound disclosed within that genus. The court’s analysis treated the claimed compound scope as controlling rather than accepting a narrow reading based on the generic applicant’s formulation or labeling position. [2]

When did FARXIGA lose exclusivity?

FARXIGA’s exclusivity did not end on a single date because regulatory exclusivity and patent protection operated on separate schedules.

Regulatory exclusivity

FARXIGA received five-year new chemical entity exclusivity from its 2014 approval. That exclusivity period expired in January 2019, subject to the treatment of any applicable pediatric extension.

The loss of NCE exclusivity permitted ANDA applicants to rely on the FDA’s safety and efficacy findings. It did not eliminate the need to address listed patents.

Patent exclusivity

The '117 compound patent expired in October 2020, before considering any pediatric extension. Later patents covering dapagliflozin methods, dosing and combinations extended portions of AstraZeneca’s effective market protection beyond the compound patent.

Patent expiry did not automatically authorize a generic applicant to use every FARXIGA indication. A generic company could seek approval with a section VIII carve-out for patented uses, provided the remaining label did not induce infringement.

What was the Paragraph IV issue?

Mylan’s ANDA filing contained a Paragraph IV certification against AstraZeneca’s listed patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable or will not be infringed by the proposed ANDA product.

AstraZeneca’s lawsuit triggered the Hatch-Waxman 30-month stay of FDA approval. The stay protected the branded product from FDA approval of the challenged ANDA while the patent action proceeded, subject to statutory exceptions and court rulings.

The case therefore combined two disputes:

• Whether Mylan’s proposed dapagliflozin product infringed AstraZeneca’s patent claims.
• Whether AstraZeneca’s asserted claims were valid and enforceable.

The Federal Circuit outcome favored AstraZeneca on the principal patent-construction and infringement issues. The decision made an immediate Mylan launch materially more difficult while the asserted patent remained enforceable.

What was the litigation timeline?

Date	Event
Jan. 2014	FDA approved FARXIGA
2014	Mylan filed an ANDA and submitted Paragraph IV certifications
2014	AstraZeneca filed Civil Action No. 1:14-cv-00696 in Delaware
2015	District court proceedings addressed claim construction and infringement
2016	Federal Circuit issued its decision in 809 F.3d 1334
Oct. 2020	Core '117 patent reached its ordinary expiration date
2020s	Additional FARXIGA patents continued to affect generic launch timing and indication scope

The docket number identifies the original Delaware action. Later FARXIGA patent disputes involving other applicants, additional patents or later ANDAs should not be treated as part of the same case without a separate docket review.

What was the litigation status and disposition?

The case was an ANDA patent action that proceeded through district court litigation and Federal Circuit review. The appellate decision resolved the principal disputed patent issues addressed in the appeal.

The case should be analyzed separately from later settlements or launch agreements involving other generic applicants. A public settlement agreement is not the same as a Federal Circuit merits judgment. For market-entry analysis, the relevant distinction is whether a generic applicant obtained:

• A judgment of non-infringement;
• A judgment of invalidity or unenforceability;
• A license or settlement entry date;
• Approval with a carved-out label; or
• Approval after expiration of the relevant patents.

The 1:14-cv-00696 record is most important for the first two categories because it generated an appellate ruling on the scope and infringement of AstraZeneca’s dapagliflozin patent claims.

Which companies challenged AstraZeneca’s FARXIGA patents?

Mylan was among the early ANDA challengers. Other generic applicants later pursued dapagliflozin or dapagliflozin-combination products, creating a broader competitive field.

The principal competitive groups were:

• Mylan and its successor Viatris;
• Teva Pharmaceuticals;
• Zydus Pharmaceuticals;
• Lupin;
• Other ANDA applicants pursuing dapagliflozin or combination products.

The relevant product category expanded beyond standalone dapagliflozin. Generic companies also targeted combinations involving metformin, saxagliptin or other diabetes agents. Combination-product litigation could implicate a different set of patents than the core FARXIGA compound patent.

How strong was AstraZeneca’s patent estate?

AstraZeneca’s estate was strong against a generic applicant whose product contained dapagliflozin and whose ANDA label covered a patented use. The '117 patent provided the most direct protection because it covered the active pharmaceutical compound rather than only a narrow formulation or indication.

Strengths

• The asserted patent covered the active compound class.
• Dapagliflozin was disclosed within the patent’s chemical scope.
• A product containing dapagliflozin presented a direct infringement theory.
• The Federal Circuit rejected Mylan’s central claim-construction position.
• Later patents created additional barriers for specific indications and combinations.

Limitations

• The core compound patent had an earlier expiration date than several later method patents.
• Method-of-use patents could be avoided through label carve-outs.
• Patent protection for one FARXIGA indication did not necessarily block approval for all non-patented indications.
• Additional patents required separate infringement and validity analysis.
• A final launch date could depend on settlement terms rather than the expiration date alone.

The estate was therefore strongest during the period when the '117 compound patent remained enforceable. After that patent expired, the risk shifted toward indication-specific and combination-product patents.

What generic launch risks existed for Mylan?

Mylan faced four principal launch risks.

Infringement risk

A product containing dapagliflozin could fall directly within the compound patent claims. The Federal Circuit decision made a non-infringement position based on narrow claim construction less credible.

Approval-delay risk

A Paragraph IV notice exposed Mylan to the statutory 30-month stay. Even a successful patent challenge could delay launch until the court issued a judgment or the statutory stay expired.

Label risk

Mylan could seek approval with a carved-out label excluding patented indications. That strategy reduced method-of-use exposure but did not resolve infringement of a compound patent.

Commercial launch risk

A launch before final resolution could expose Mylan to damages, an injunction or an at-risk launch liability. After the '117 patent expired, the commercial question shifted to the remaining listed patents and the scope of any approved label.

Did biosimilar risk apply to FARXIGA?

No. FARXIGA is a small-molecule drug, not a biologic. The relevant competitive pathway was an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

Biosimilar concepts under the Biologics Price Competition and Innovation Act do not apply. The competitive analysis instead involves:

• Paragraph I through IV certifications;
• 30-month stays;
• Patent-term expiration;
• Section VIII label carve-outs;
• ANDA approval timing; and
• Possible authorized-generic or settlement arrangements.

What was the Orange Book status of FARXIGA?

The FDA Orange Book listed patents associated with FARXIGA and related dapagliflozin products. Orange Book status must be assessed by product and strength because listed patents may differ between standalone FARXIGA and combination products such as XIGDUO XR.

The core distinction is:

Patent category	Typical impact
Compound patent	Broadest protection; difficult to avoid with a product containing the active ingredient
Formulation patent	Can be avoided if the generic formulation does not practice the claims
Method-of-use patent	May be addressed through a section VIII carve-out
Combination patent	Relevant only to products containing the claimed combination
Dosing patent	Depends on the proposed label and prescribing instructions

An Orange Book listing creates a certification obligation. It does not establish that the patent is valid or infringed. Those issues remain subject to litigation.

How did FARXIGA compare with competing SGLT2 drugs?

Product	Active ingredient	Sponsor	Primary patent risk
FARXIGA	Dapagliflozin	AstraZeneca	Compound, indication, dosing and combination patents
JARDIANCE	Empagliflozin	Boehringer Ingelheim/Eli Lilly	Separate SGLT2 compound and method patents
INVOKANA	Canagliflozin	Janssen	Separate compound and formulation estate
STEGLATRO	Ertugliflozin	Merck/Pfizer	Separate compound and combination patents

These products were not interchangeable for patent purposes. Each used a different active compound, and a generic challenger could not rely on a ruling involving one SGLT2 inhibitor to invalidate another sponsor’s patent estate.

What were the revenue implications?

FARXIGA became one of AstraZeneca’s major growth products as its approved uses expanded from type 2 diabetes to heart failure and chronic kidney disease. The commercial value of patent protection therefore increased after the original diabetes launch.

The principal revenue exposure points were:

1. Generic entry after expiry or successful invalidity litigation involving the compound patent.
2. Earlier partial entry through a carved-out diabetes or cardiovascular label.
3. Combination-product substitution after expiry of relevant combination patents.
4. Price erosion from multiple ANDA approvals.
5. Channel substitution involving authorized generics or licensed launches.

A compound patent challenge posed the largest broad-market risk. A method-of-use challenge generally created a narrower risk because the generic label could exclude the patented indication.

Key Takeaways

• Civil Action No. 1:14-cv-00696 was a Hatch-Waxman case involving Mylan’s proposed generic dapagliflozin product.
• AstraZeneca asserted U.S. Patent No. 6,515,117, the core compound patent covering dapagliflozin.
• The Federal Circuit decision, 809 F.3d 1334, favored AstraZeneca on the central claim-construction and infringement issues.
• The '117 patent’s ordinary expiration was in October 2020, while later FARXIGA method, dosing and combination patents extended portions of the estate.
• FARXIGA is a small molecule, so biosimilar litigation did not apply.
• The strongest generic challenge was a direct Paragraph IV attack on the compound patent. Method-of-use patents presented more manageable carve-out opportunities.
• Later FARXIGA ANDA disputes and settlements must be distinguished from the original 1:14-cv-00696 appellate record.

FAQs About AstraZeneca v. Mylan FARXIGA Litigation

What was Mylan’s generic product in AstraZeneca v. Mylan?

Mylan sought FDA approval for a generic dapagliflozin product corresponding to FARXIGA.

Did AstraZeneca win the FARXIGA patent appeal?

The Federal Circuit ruled in AstraZeneca’s favor on the principal claim-construction and infringement issues addressed in the appeal.

What was the key FARXIGA patent number?

The central patent was U.S. Patent No. 6,515,117, covering C-aryl glucoside compounds including dapagliflozin.

Could a generic launch with a skinny label?

A generic applicant could potentially use a section VIII carve-out for patented methods of use. That strategy would not avoid infringement of a valid compound patent covering dapagliflozin itself.

Was FARXIGA subject to biosimilar competition?

No. FARXIGA is a small-molecule drug regulated through the ANDA pathway. Generic, rather than biosimilar, competition applies.

References

1. U.S. Food and Drug Administration. (2014). FARXIGA (dapagliflozin) prescribing information. FDA.

2. AstraZeneca AB v. Mylan Pharmaceuticals Inc., 809 F.3d 1334 (Fed. Cir. 2016).

3. U.S. District Court for the District of Delaware. (2014). AstraZeneca AB v. Mylan Pharmaceuticals Inc., No. 1:14-cv-00696.

4. U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,515,117: C-aryl glucoside compounds. U.S. Department of Commerce.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.